DOLLAR GENERAL CORP COM $992,795,576 17,584,052 1,114,471 AGL RESOURCES INC COM $426,410,182 9,263,745 1,103,235 PIER 1 IMPORTS INC COM...
DJ CFA SOURCE: SEC 13F-HR FILER: The Vanguard Group, Inc. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/07/2013 Up to 200 of the largest sales of...
SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided...
SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to launch a new premium advanced skin...
SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the...
SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the...
SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501...
SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue...
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter...
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket...
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously...
SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock...
SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the publication of positive findings from the...
Important Clinical Findings Provide New Therapeutic Insights into Healing Potential of Cardium's Matrix Technology Platform SAN DIEGO, Oct. 14...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads